PT00114第1阶段的成果是积极的。 PT00114是稀有基因疾病的潜在治疗方法,显示了安全和生物活动。 Protagenic Therapeutics reports positive Phase 1 results for PT00114, a potential treatment for rare genetic disorders, showing safety and biological activity.

治疗学报告称,其第一阶段对PT00114的多剂量研究取得了积极成果,PT00114是对稀有遗传疾病的一种新型调查疗法。 Protagenic Therapeutics reports positive results from its Phase 1 multiple-dose study of PT00114, a novel investigational therapy for rare genetic disorders. 试验表明,PT00114在所有剂量水平上都能耐受,没有严重的不良反应. The trial demonstrated that PT00114 was well-tolerated across all dose levels, with no serious adverse events. 参与者显示了生物活动的迹象,包括关键生物标志中的预期目标参与和剂量依赖反应。 Participants showed signs of biological activity, including expected target engagement and dose-dependent responses in key biomarkers. 该公司计划将PT00114推进到第二阶段试验,以进一步评价功效和安全。 The company plans to advance PT00114 into Phase 2 trials to further evaluate efficacy and safety.